SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2013 07:00

RNS Number : 9350P
Victrex PLC
08 October 2013
 



 

 

8 October 2013

Victrex plc - Year End Trading Statement

Victrex plc ('Victrex'), an innovative world leader in high performance polymers, today releases its year end trading statement, ahead of its 2013 preliminary results which will be announced on Tuesday 10 December 2013.

Full year sales volume was slightly ahead of last year at 2,920 tonnes (FY 2012: 2,904 tonnes) following a robust second half performance, with sales volume approximately 10% ahead of the first half year. Group sales volume of 1,528 tonnes for the second half was in line with the strong prior year performance (H2 2012: 1,527 tonnes), with good progress across our industrial and transport markets, offset by lower sales in the electronics market following the non-recurrence of last year's strong product launch related sales into consumer electronics.

In our Invibio Biomaterial Solutions business, full year revenue was slightly ahead of the prior year at £50.8m (FY 2012: £50.5m). This reflects steady improvement in sales to the Spine market during the second half year, with revenue 10% ahead of the first half, as inventory levels in the industry appear to have stabilised. Second half revenue in Invibio was also ahead of the prior year at £26.6m (H2 2012: £25.0m). Outside of the Spine market, we continue to see steady progress in our emerging market opportunities.

Outlook

Looking ahead to our new financial year, whilst we remain mindful of the wider economic environment, our order book for October is reassuring. Victrex remains confident in the diverse and multiple growth opportunities that are being developed across the business. Our investment in additional capacity, which is a key enabler to support and deliver our future growth programmes, remains on plan and on budget, with construction progressing well.

Victrex will host an Investor Day, 'Spotlight on Growth', in London this Thursday, 10 October 2013, with its Executive Management Team, including presentations by Tim Cooper, Managing Director of VPS, and Martin Court, Managing Director of Invibio, covering the scale of Victrex's Group wide growth programmes. No new trading or financial information will be disclosed during the Investor Day. 

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations 01253 898121

Steve Barrow, Group Finance Director 01253 897700

 

MHP Communications:

Nick Denton/Barnaby Fry/James White 0203 128 8100

 

Investor and analyst conference call:

A conference call for Investors and Analysts will be held today, Tuesday 8 October, 09.00am. For further details please contact Ben Griffiths at MHP Communications on 0203 128 8100.

 

About Victrex:

Victrex is an innovative world leader in high performance polymers. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 30 years' experience, we are investing in technology leadership to deliver new solutions to our customers and our markets. Find out more at www.victrexplc.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGWAUUPWGQM
Date   Source Headline
11th Oct 20194:18 pmRNSHolding(s) in Company
8th Oct 20193:09 pmRNSHolding(s) in Company
7th Oct 20194:06 pmRNSHolding(s) in Company
3rd Oct 20194:18 pmRNSHolding(s) in Company
30th Sep 201911:53 amRNSTotal Voting Rights
18th Sep 20199:19 amRNSDirector/PDMR Shareholding
30th Aug 20199:00 amRNSTotal Voting Rights
19th Aug 201911:44 amRNSDirector/PDMR Shareholding
14th Aug 201910:39 amRNSHolding(s) in Company
31st Jul 20199:01 amRNSTotal Voting Rights
25th Jul 20197:00 amRNSInterim Management Statement
17th Jul 201910:38 amRNSDirector/PDMR Shareholding
28th Jun 20199:00 amRNSTotal Voting Rights
24th Jun 20197:00 amRNSDirectorate Change
18th Jun 201910:42 amRNSDirector/PDMR Shareholding
3rd Jun 20191:55 pmRNSBlock listing Interim Review
31st May 20193:12 pmRNSDirector/PDMR Shareholding
31st May 20199:00 amRNSTotal Voting Rights
20th May 201910:09 amRNSDirector/PDMR Shareholding
17th May 201910:50 amRNSDirector/PDMR Shareholding
15th May 20198:49 amRNSDirector/PDMR Shareholding
13th May 20197:00 amRNSHalf-year Report
30th Apr 201910:00 amRNSTotal Voting Rights
17th Apr 201912:03 pmRNSDirector/PDMR Shareholding
29th Mar 201912:07 pmRNSTotal Voting Rights
19th Mar 201910:55 amRNSDirector/PDMR Shareholding
28th Feb 20199:33 amRNSTotal Voting Rights
19th Feb 201910:42 amRNSDirector/PDMR Shareholding
18th Feb 20194:23 pmRNSDirector/PDMR Shareholding
11th Feb 20194:34 pmRNSHolding(s) in Company
8th Feb 20199:44 amRNSHolding(s) in Company
6th Feb 20192:28 pmRNSResult of AGM
6th Feb 20191:55 pmRNSDirector/PDMR Shareholding
6th Feb 20197:00 amRNSAGM and Q1 Interim Management Statement
4th Feb 201912:18 pmRNSDirector/PDMR Shareholding
31st Jan 20199:29 amRNSTotal Voting Rights
28th Jan 20194:28 pmRNSHolding(s) in Company
17th Jan 201911:21 amRNSDirector/PDMR Shareholding
11th Jan 20193:44 pmRNSHolding(s) in Company
3rd Jan 20191:00 pmRNSAnnual Financial Report
31st Dec 20189:00 amRNSTotal Voting Rights
18th Dec 20183:19 pmRNSDirector/PDMR Shareholding
18th Dec 201810:30 amRNSDirector/PDMR Shareholding
17th Dec 201811:40 amRNSDirector/PDMR Shareholding
11th Dec 20189:50 amRNSDirector/PDMR Shareholding
11th Dec 20189:48 amRNSDirector/PDMR Shareholding
5th Dec 20181:47 pmRNSDirector/PDMR Shareholding
5th Dec 201812:35 pmRNSDirector/PDMR Shareholding
4th Dec 20187:00 amRNSPreliminary Results 2018
3rd Dec 20189:25 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.